References
- Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N: Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008; 122: 1089–1094.
- Park SH, Knobf MT, Sutton KM: Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms. Clin J Oncol Nurs 2012; 16: 260–266.
- Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J et al.: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111: 365–372.
- Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D et al.: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877–3883.
- Zivian MT, Salgado B: Side Effects Revisited: Women’s Experiences with Aromatase Inhibitors. Breast Cancer Action, San Francisco 2008.
- Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62.
- Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS et al.: Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer 2013; 119: 2375–2382.
- Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012; 134: 459–478.
- Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556–562.
- Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C: Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013; 108: 1515–1524.
- Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C: Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010; 120: 127–134.
- Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S et al.: Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009; 27: 4955–4960.
- Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J et al.: Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104: 87–91.
- Shanmugam VK, McCloskey J, Elston B, Allison SJ, Eng-Wong J: The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Res Treat 2012; 131: 699–708.
- Henry NL, Jacobson JA, Banerjee M, Hayden J, Smerage JB, Van Poznak C et al.: A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 2010; 116: 4360–4367.
- Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R et al.: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26: 3147–3152.
- Singer O, Cigler T, Moore AB, Levine AB, Hentel K, Belfi L et al.: Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) 2012; 64: 1910–1918.
- Lintermans A, Laenen A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J et al.: Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol 2013; 24: 350–355.
- Sarvazyan AP, Rudenko OV, Swanson SD, Fowlkes JB, Emelianov SY: Shear wave elasticity imaging: a new ultrasonic technology of medical diagnostics. Ultrasound Med Biol 1998; 24: 1419–1435.
- Taljanovic MS, Gimber LH, Becker GW, Latt LD, Klauser AS, Melville DM et al.: Shear-wave elastography: basic physics and musculoskeletal applications. Radiographics 2017; 37: 855–870.
- Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA et al.: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 2019; 37: 423–438.
- Dirrichs T, Quack V, Gatz M, Tingart M, Kuhl CK, Schrading S: Shear wave elastography (SWE) for the evaluation of patients with tendinopathies. Acad Radiol 2016; 23: 1204–1213.
- Ham S, Kim S, Choi H, Lee Y, Lee H: Greater muscle stiffness during contraction at menstruation as measured by shear-wave elastography. Tohoku J Exp Med 2020; 250: 207–213.
- Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scire CA: Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open 2017; 3: e000523.